Vitamin D analogs

Endocrinology and Metabolism Clinics of North America

Volumn 39, Issue 2, 2010, Pages 447-472

  Jones, Glenville ^a  

^a QUEEN S UNIVERSITY   (Canada)

Author keywords

Calcitriol; Calcium and phosphate homeostasis; Cell differentiation; Vitamin D analogs

Indexed keywords

1,25 DIHYDROXYERGOCALCIFEROL; 2BETA (3 HYDROXYPROPOXY)CALCITRIOL; CALCIDIOL 1 MONOOXYGENASE; CALCIFEDIOL; CALCIPOTRIOL; CALCITRIOL; CALCITRIOL DERIVATIVE; CALCIUM; COLECALCIFEROL; CYTOCHROME P450; CYTOCHROME P450 24A1; CYTOCHROME P450 24A1 INHIBITOR; CYTOCHROME P450 27B1; CYTOCHROME P450 3A4; CYTOCHROME P450 INHIBITOR; DIHYDROTACHYSTEROL; DOXERCALCIFEROL; ELOCALCITOL; ERGOCALCIFEROL; FIBROBLAST GROWTH FACTOR 23; NUCLEAR RECEPTOR COACTIVATOR 2; PARATHYROID HORMONE; PARICALCITOL; PRODRUG; RETINOID X RECEPTOR; SEOCALCITOL; UNCLASSIFIED DRUG; UNINDEXED DRUG; VITAMIN D BINDING PROTEIN; VITAMIN D DERIVATIVE; VITAMIN D RECEPTOR;

BINDING AFFINITY; BREAST CANCER; BREAST TUMOR; CALCIUM BLOOD LEVEL; CANCER THERAPY; CATABOLISM; CELL DIFFERENTIATION; CELL PROLIFERATION; CHRONIC KIDNEY DISEASE; DIETARY INTAKE; DRUG BIOAVAILABILITY; DRUG DOSE ESCALATION; DRUG HALF LIFE; DRUG MECHANISM; DRUG METABOLISM; DRUG RECEPTOR BINDING; DRUG STRUCTURE; DRUG SYNTHESIS; HUMAN; HYDROXYLATION; HYPERCALCEMIA; LIVER CLEARANCE; LOW DRUG DOSE; NONHUMAN; OSTEOMALACIA; OSTEOPOROSIS; PARATHYROID HORMONE BLOOD LEVEL; PRIORITY JOURNAL; PROSTATE DISEASE; PROTEIN BINDING; PSORIASIS; REVIEW; RICKETS; SECONDARY HYPERPARATHYROIDISM; STRUCTURE ACTIVITY RELATION; TARGET CELL; VITAMIN BLOOD LEVEL; VITAMIN SUPPLEMENTATION;

ANIMALS; FEMALE; HUMANS; HYPERPARATHYROIDISM, SECONDARY; MALE; MICE; NEOPLASMS; PSORIASIS; RATS; RECEPTORS, CALCITRIOL; RETINOID X RECEPTORS; VITAMIN D; VITAMIN D DEFICIENCY; VITAMIN D-BINDING PROTEIN;

EID: 77953952863     PISSN: 08898529     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.ecl.2010.02.003     Document Type: Review

References (150)

1. Holick M.F. Vitamin D deficiency. N Engl J Med 2007, 357:266-281.
2. 3. Semin Dial 2007, 20:316-324.
3. Jones G., Strugnell S., DeLuca H.F. Current understanding of the molecular actions of vitamin D. Physiol Rev 1998, 78:1193-1231.
4. 3 induces differentiation of human myeloid leukemia cells. Biochem Biophys Res Commun 1981, 102:937-943.
5. Bouillon R., Okamura W.H., Norman A.W. Structure-function relationships in the vitamin D endocrine system. Endocr Rev 1995, 16:200-257.
6. Jones G. Vitamin D and analogues. Principles of bone biology. Third edition. Section: pharmacological mechanisms of therapeutics 2008, 1777-1799. Academic Press Inc, San Diego (CA). J. Bilezikian, L. Raisz, G. Rodan (Eds.).
7. Masuda S., Jones G. The promise of vitamin D analogs in the treatment of hyperproliferative conditions. Mol Cancer Ther 2006, 5:797-808.
8. Vieth R. The pharmacology of Vitamin D, including fortification strategies. Vitamin D 2005, 995-1015. Elsevier Academic Press, New York. 2nd edition. D. Feldman, J.W. Pike, F.H. Glorieux (Eds.).
9. 3 in humans. J Clin Endocrinol Metab 2004, 89:5387-5391.
10. 3: comparative experiments in rats. Biochem Pharmacol 1960, 2:1-6.
11. 3 in the rat. Proc Soc Exp Biol Med 1985, 178:432-436.
12. 3 supplement use on serum 25OHD concentration in elderly women in summer and winter. Calcif Tissue Int 2004, 74:150-156.
13. 3 in maintaining circulating concentrations of 25-hydroxyvitamin D. J Clin Endocrinol Metab 2008, 93:677-681.
14. 3 on intestinal calcium absorption in Nigerian children with rickets. J Clin Endocrinol Metab 2009, 94:3314-3321.
15. 3. J Am Chem Soc 1973, 95:2748-2749.
16. 2. Proc Natl Acad Sci U S A 1978, 75:2080-2081.
17. 5. J Natl Cancer Inst 2000, 92:1836-1840.
18. Seeman E., Tsalamandris C., Bass S., et al. Present and future of osteoporosis therapy. Bone 1995, 17:23S-29S.
19. Riggs B.L., Melton L.J. The prevention and treatment of osteoporosis. N Engl J Med 1992, 327:620-627.
20. Morrison N.A., Qi J.C., Tokita A., et al. Prediction of bone density from vitamin D receptor alleles. Nature 1994, 367:284-287.
21. Uitterlinden A.G., Fang Y., van Meurs J.B.J., et al. Analog metabolism. Vitamin D 2005, 1121-1158. Academic Press, San Diego (CA). 2nd edition. D. Feldman, W. Pike, F. Glorieux (Eds.).
22. 3. Bone Miner 1987, 3:47-52.
23. 2 on calcium homeostasis in postmenopausal osteopenic women. J Bone Miner Res 1994, 9:607-614.
24. Gallagher J.C., Riggs B.L., Recker R.R., et al. The effect of calcitriol on patients with postmenopausal osteoporosis with special reference to fracture frequency. Proc Soc Exp Biol Med 1989, 191:287-292.
25. Ott S., Chesnut C.H. Calcitriol treatment is not effective in post-menopausal osteoporosis. Ann Intern Med 1989, 110:267-274.
26. Tilyard M.W., Spears G.F.S., Thomson J., et al. Treatment of post-menopausal osteoporosis with calcium. N Engl J Med 1992, 326:357-362.
27. 3 formed in the isolated perfused rat kidney: a model for the study of side-chain metabolism of vitamin D. Biochemistry 1988, 27:7070-7079.
28. Qaw F., Calverley M.J., Schroeder N.J., et al. In vivo metabolism of the vitamin D analog, dihydrotachysterol. Evidence for formation of 1α,25-and 1β,25-dihydroxydihydrotachysterol metabolites and studies of their biological activity. J Biol Chem 1993, 268:282-292.
29. Kragballe K., Gjertsen B.T., De Hoop D., et al. Double-blind, right/left comparison of calcipotriol and betamethasone valerate in treatment of psoriasis vulgaris. Lancet 1991, 337:193-196.
30. Nishii Y., Sato K., Kobayashi T. The development of vitamin D analogues for the treatment of osteoporosis. Osteoporos Int 1993, 1(Suppl):S190-3.
31. 2 made in the human hepatoma, Hep3B. Biochem J 1995, 310:233-241.
32. Baggiolini E.G., Partridge J.J., Shiuey S.-J., et al. Cholecalciferol 23-yne derivatives, their pharmaceutical compositions, their use in the treatment of calcium related diseases, and their antitumor activity, US 4,804,502. Chem Abstr 1989, 111:58160d. [abstract].
33. 3 analogs stabilize helix 12 of the vitamin D receptor. Chem Biol 2008, 15:1029-1034.
34. Verstuyf A., Verlinden L., van Etten E., et al. Biological activity of CD-ring modified 1α,25-dihydroxyvitamin D analogues: C-ring and five-membered D-ring analogues. J Bone Miner Res 2000, 15:237-252.
35. 3, increases bone mineral density regardless of serum 25(OH)D levels in osteoporotic subjects. J Steroid Biochem Mol Biol 2007, 103:584-586.
36. 3 analogues and their docking to vitamin D receptors. J Org Chem 2001, 66:8760-8771.
37. 3 selectively induces bone formation. Proc Natl Acad Sci U S A 2002, 99:13487-13491.
38. Crescioli C., Ferruzzi P., Caporali A., et al. Inhibition of prostate cell growth by BXL-628, a calcitriol analogue selected for a phase II clinical trial in patients with benign prostate hyperplasia. Eur J Endocrinol 2004, 150:591-603.
39. Adorini L., Penna G., Amuchastegui S., et al. Inhibition of prostate growth and inflammation by the vitamin D receptor agonist BXL-628 (elocalcitol). J Steroid Biochem Mol Biol 2007, 103:689-693.
40. 3. Chem Biol 1999, 6:265-275.
41. Ma Y., Khalifa B., Yee Y.K., et al. Identification and characterization of noncalcemic, tissue-selective, nonsecosteroidal vitamin D receptor modulators. J Clin Invest 2006, 116:892-904.
42. 3-26,23-lactone, a vitamin D receptor antagonist that inhibits osteoclast formation and bone resorption in bone marrow cultures from patients with Paget's disease. Endocrinology 2005, 146:2023-2030.
43. Saito N., Kittaka A. Highly potent vitamin D receptor antagonists: design, synthesis, and biological evaluation. Chembiochem 2006, 7:1479-1490.
44. 3 receptor antagonists. Mol Pharmacol 2001, 59:1478-1485.
45. Prosser D.E., Jones G. Enzymes involved in the activation and inactivation of vitamin D. Trends Biochem Sci 2004, 29:664-673.
46. Schuster I., Egger H., Astecker N., et al. Selective inhibitors of CYP24: mechanistic tools to explore vitamin D metabolism in human keratinocytes. Steroids 2001, 66:451-462.
47. 3. J Steroid Biochem Mol Biol 2004, 89-90:5-12.
48. Posner G, Petkovich M. Vitamin D analogues targeting CYP24 in chronic kidney disease [abstract]. Proceedings of the 14th Workshop on Vitamin D. Brugge, Belgium, October 4-8, 2009. p. 7.
49. Bikle D.D. Clinical counterpoint: vitamin D: new actions, new analogs, new therapeutic potential. Endocr Rev 1992, 13:765-784.
50. Bischoff-Ferrari H.A., Giovannucci E., Willett W.C., et al. Estimation of optimal serum concentrations of 25-hydroxyvitamin D for multiple health outcomes. Am J Clin Nutr 2006, 84:18-28.
51. Quarles L.D. Endocrine functions of bone in mineral metabolism regulation. J Clin Invest 2008, 118:3820-3828.
52. Delmez J.A., Tindira C., Grooms P., et al. Parathyroid hormone suppression by intravenous 1,25-dihydroxyvitamin D. A role for increased sensitivity to calcium. J Clin Invest 1989, 83:1349-1355.
53. K/DOQI clinical practise guidelines for bone metabolism and disease in chronic kidney disease. Am J Kidney Dis 2003, 42(Suppl 3). S1-202.
54. Gonzalez E.A., Sachdeva A., Oliver D.A., et al. Vitamin D insufficiency and deficiency in chronic kidney disease. A single center observational study. Am J Nephrol 2004, 24:503-510.
55. Al-Aly Z., Qazi R.A., González E.A., et al. Changes in serum 25-hydroxyvitamin D and plasma intact PTH levels following treatment with ergocalciferol in patients with CKD. Am J Kidney Dis 2007, 50:59-68.
56. Zisman A.L., Hristova M., Ho L.T., et al. Impact of ergocalciferol treatment of vitamin D deficiency on serum parathyroid hormone concentrations in chronic kidney disease. Am J Nephrol. 2007, 27:36-43.
57. Dusso A., Lopez-Hilker S., Rapp N., et al. Extra-renal production of calcitriol in chronic renal failure. Kidney Int 1988, 34:368-375.
58. Fournier A., Harbouche L., Mansour J., et al. Impact of calcium and vitamin D therapy on arterial and cardiac disease in young adults with childhood-onset end stage renal disease. Nephrol Dial Transplant 2007, 22:956-957.
59. Teng M., Wolf M., Ofsthun M.N., et al. Activated injectable vitamin D and hemodialysis survival: a historical cohort study. J Am Soc Nephrol 2005, 16:1115-1125.
60. Tentori F., Hunt W.C., Stidley C.A., et al. Mortality risk among hemodialysis patients receiving different vitamin D analogs. Kidney Int 2006, 70:1858-1865.
61. Mathew S., Lund R.J., Chaudhary L.R., et al. Vitamin D receptor activators can protect against vascular calcification. J Am Soc Nephrol 2008, 19:1509-1519.
62. Judd S.E., Tangpricha V. Vitamin D deficiency and risk for cardiovascular disease. Am J Med Sci 2009, 338:40-44.
63. Colston K.W., Pirianov G., Bramm E., et al. Effects of Seocalcitol (EB1089) on nitrosomethyl urea-induced rat mammary tumors. Breast Cancer Res Treat 2003, 80:303-311.
64. Gulliford T., English J., Colston K.W., et al. A phase I study of the vitamin D analogue EB 1089 in patients with advanced breast and colorectal cancer. Br J Cancer 1998, 78:6-13.
65. Evans T.R., Colston K.W., Lofts F.J., et al. A phase II trial of the vitamin D analogue Seocalcitol (EB1089) in patients with inoperable pancreatic cancer. Br J Cancer 2002, 86:680-685.
66. Dalhoff K., Dancey J., Astrup L., et al. A phase II study of the vitamin D analogue, Seocalcitol in patients with inoperable hepatocellular carcinoma. Br J Cancer 2003, 89:252-257.
67. Beer T.M., Myrthue A., Garzotto M. Randomized study of high-dose pulse calcitriol or placebo prior to radical prostatectomy. Cancer Epidemiol Biomarkers Prev 2004, 13:2225-2232.
68. Trump D.L., Hershberger P.A., Bernardi R.J., et al. Anti-tumor activity of calcitriol: pre-clinical and clinical studies. J Steroid Biochem Mol Biol 2004, 89-90:519-526.
69. Deeb K.K., Trump D.L., Johnson C.S. Vitamin D signalling pathways in cancer: potential for anticancer therapeutics. Nat Rev Cancer 2007, 7:684-700.
70. 3 occurs through the vitamin D receptor and the vitamin D-responsive element. J Bone Miner Res 1994, 9:1981-1987.
71. Jones G. Pharmacokinetics of Vitamin D toxicity. Am J Clin Nutr 2008, 88(Suppl):582S-586S.
72. Okuda K.I., Usui E., Ohyama Y. Recent progress in enzymology and molecular biology of enzymes involved in vitamin D metabolism. J Lipid Res 1995, 36:1641-1652.
73. Cheng J.B., Levine M.A., Bell N.H., et al. Genetic evidence that the human CYP2R1 enzyme is a key vitamin D 25-hydroxylase. Proc Natl Acad Sci U S A 2004, 101:7711-7715.
74. Jones G., Byford V., West S., et al. Hepatic activation and inactivation of clinically-relevant vitamin D Analogs and prodrugs. Anticancer Res 2006, 26:2589-2596.
75. 3. J Mol Biol 2008, 380:95-106.
76. 3 sterols by cultured alveolar macrophages from patients with sarcoidosis. J Exp Med 1985, 161:755-765.
77. St.Arnaud R., Messerlian S., Moir J.M., et al. The 25-hydroxyvitamin D 1-α-hydroxylase gene maps to the pseudovitamin D-deficiency rickets (PDDR) disease locus. J Bone Miner Res 1997, 12:1552-1559.
78. 3 1α-hydroxylase and vitamin D synthesis. Science 1997, 277:1827-1830.
79. Fu G.K., Lin D., Zhang M.Y., et al. Cloning of human 25-hydroxyvitamin D-1α-hydroxylase and mutations causing vitamin D-dependent rickets type 1. Mol Endocrinol 1997, 11:1961-1970.
80. Jones G., Ramshaw H., Zhang A., et al. Expression and activity of vitamin D-metabolizing cytochrome P450s (CYP1α and CYP24) in human non-small cell lung carcinomas. Endocrinology 1999, 140:3303-3310.
81. Hewison M., Adams J. Extra-renal 1α-Hydroxylase activity and human disease. Vitamin D 2005, 1379-1402. Academic Press, San Diego (CA). 2nd edition. D. Feldman, W. Pike, F. Glorieux (Eds.).
82. Bouillon R., Allewaert K., Xiang D.Z., et al. Vitamin D analogs with low affinity for the vitamin D binding protein: enhanced in vitro and decreased in vivo activity. J Bone Miner Res 1991, 6:1051-1057.
83. Kissmeyer A.-M., Mathiasen I.S., Latini S., et al. Pharmacokinetic studies of vitamin D analogues: Relationship to vitamin D binding protein (DBP). Endocrine 1995, 3:263-266.
84. 3 analogue, 22-oxacalcitriol (OCT): its different behaviour from calcitriol in plasma transport system. Vitamin D: gene regulation structure-function analysis and clinical application 1991, 312-313. De Gruyter, Berlin. A.W. Norman, R. Bouillon, M. Thomasset (Eds.).
85. 3 is due to reduced catabolism and altered protein binding. Biochem Pharmacol 1994, 47:987-993.
86. Safadi F.F., Thornton P., Magiera H., et al. Osteopathy and resistance to vitamin D toxicity in mice null for vitamin D binding protein. J Clin Invest 1999, 103:239-251.
87. Whitfield G.K., Jurutka P.W., Haussler C., et al. Nuclear receptor: structure-function, molecular control of gene transcription and novel bioactions. Vitamin D 2005, 219-262. Elsevier Academic Press, New York. 2nd edition. D. Feldman, J.W. Pike, F.H. Glorieux (Eds.).
88. Rochel N., Tocchini-Valentini G., Egea P.F., et al. Functional and structural characterization of the insertion region in the ligand binding domain of the vitamin D nuclear receptor. Eur J Biochem 2001, 268:971-979.
89. 3 receptor: a network of coactivator interactions. Gene 2000, 246:9-21.
90. Yoshizawa T., Handa Y., Uematsu Y., et al. Mice lacking the vitamin D receptor exhibit impaired bone formation, uterine hypoplasia and growth retardation after weaning. Nat Genet 1997, 16:391-396.
91. Li Y.C., Pirro A.E., Amling M., et al. Targeted ablation of the vitamin D receptor: an animal model of vitamin D-dependent rickets type II with alopecia. Proc Natl Acad Sci U S A 1997, 94:9831-9835.
92. Stern P. A monolog on analogs. In vitro effects of vitamin D metabolites and consideration of the mineralisation question. Calcif Tissue Int 1981, 33:1-4.
93. 3 receptor. J Biol Chem 1999, 274:16838-16845.
94. Dilworth F.J., Williams G.R., Kissmeyer A.M., et al. The vitamin D analog, KH1060 is rapidly degraded both in vivo and in vitro via several pathways: principal metabolites generated retain significant biological activity. Endocrinology 1997, 138:5485-5496.
95. 3 results from a selective and prolonged induction of intestinal calcium-regulating genes. Endocrinology 2009, 150:3448-3456.
96. 3. Mol Endocrinol 1995, 9:1814-1824.
97. Rachez C., Lemon B.D., Suldan Z., et al. Ligand-dependent transcription activation by nuclear receptors requires the DRIP complex. Nature 1999, 398:824-828.
98. Takeyama K., Masuhiro Y., Fuse H., et al. Selective interaction of vitamin D receptor with transcriptional coactivators by a vitamin D analog. Mol Cell Biol 1999, 19:1049-1055.
99. Issa L.L., Leong G.M., Sutherland R.L., et al. Vitamin D analogue-specific recruitment of vitamin D receptor coactivators. J Bone Miner Res 2000, 17:879-890.
100. 3. J Cell Biochem 2003, 88:267-273.
101. 3 on genes involved in calcium homeostasis. J Bone Miner Res 2007, 22(Suppl 2):V16-9.
102. 3 to calcitroic acid. Evidence for a pathway in kidney and bone involving 24-oxidation. Biochem J 1989, 262:173-180.
103. Akiyoshi-Shibata M., Sakaki T., Ohyama Y., et al. Further oxidation of hydroxycalcidiol by calcidiol 24-hydroxylase-a study with the mature enzyme expressed in Escherichia coli. Eur J Biochem 1994, 224:335-343.
104. 3 in target cells. J Nutr Sci Vitaminol 1992, (Special Issue):75-78.
105. 2 normalizes bone morphology and serum parathyroid hormone without hypercalcemia in 25-hydroxyvitamin D-1-hydroxylase (CYP27B1)-deficient mice, an animal model of vitamin D deficiency with secondary hyperparathyroidism. J Endocrinol Invest 2008, 31:711-717.
106. 3 in the blood and tissues of the 25-hydroxyvitamin D-24-hydroxylase (CYP24A1) null mouse. Endocrinology 2005, 146:825-834.
107. 3 in long bones of rats. Calcif Tissue Int 1986, 38:79-86.
108. St Arnaud R., Arabian A., Travers R., et al. Deficient mineralization of intramembranous bone in vitamin D-24-hydroxylase-ablated mice is due to elevated 1,25-dihydroxyvitamin D and not to the absence of 24,25-dihydroxyvitamin D. Endocrinology 2000, 141:2658-2666.
109. St Arnaud. 24(R),25-(OH)2D3 administration corrects bone defect in cyp24-null mouse. 14th Workshop on Vitamin D. Brugge, Belgium, October 4-8, 2009.
110. Masuda S., Strugnell S., Calverley M.J., et al. In vitro metabolism of the anti-psoriatic vitamin D analog, calcipotriol, in two cultured human keratinocyte models. J Biol Chem 1994, 269:4794-4803.
111. Masuda S., Byford V., Kremer R., et al. In vitro metabolism of the vitamin D analog, 22-oxacalcitriol, using cultured osteosarcoma, hepatoma and keratinocyte cell lines. J Biol Chem 1996, 271:8700-8708.
112. Shankar V.N., Dilworth F.J., Makin H.L., et al. Metabolism of the vitamin D analog EB1089 by cultured human cells: redirection of hydroxylation site to distal carbons of the side chain. Biochem Pharmacol 1997, 53:783-793.
113. 3, is in part due to its metabolism into stable intermediary metabolites with significant biological activity. J Steroid Biochem Mol Biol 1999, 71:111-121.
114. Shankar V.N., Byford V., Prosser D.E., et al. Metabolism of a 20-methyl substituted series of vitamin D analogs by cultured human cells: apparent reduction of 23-hydroxylation of the side chain by 20-methyl group. Biochem Pharmacol 2001, 61:893-902.
115. Sorensen H., Binderup L., Calverley M.J., et al. In vitro metabolism of calcipotriol (MC 903), a vitamin D analogue. Biochem Pharmacol 1990, 39:391-393.
116. Kissmeyer A.M., Binderup E., Binderup L., et al. The metabolism of the vitamin D analog EB 1089: identification of in vivo and in vitro metabolites and their biological activities. Biochem Pharmacol 1997, 53:1087-1097.
117. 3 analogue. Bioorg Med Chem Lett 1992, 2:1713-1716.
118. 3: implications for drug-induced osteomalacia. Mol Pharmacol 2005, 69:56-65.
119. 3. Mol Pharmacol 2001, 60:1399-1406.
120. Onodera K., Takahashi A., Mayanagi H., et al. Phenytoin-induced bone loss and its prevention with alfacalcidol or calcitriol in growing rats. Calcif Tissue Int 2001, 69:109-116.
121. Gascon-Barre M., Villeneuve J.P., Lebrun L.H. Effect of increasing doses of phenytoin on the plasma 25-hydroxyvitamin D and 1,25-dihydroxyvitamin D concentrations. J Am Coll Nutr 1984, 3:45-50.
122. 2 and calcitriol effects in an adenine-induced uremic model of CKD reveals differential control over calcium and phosphate [abstract]. Amer Soc Bone Mineral Soc 2008.
123. 3-mediated rapid and genomic responses. Vitamin D 2005, 381-407. Academic Press, San Diego (CA). 2nd edition. D. Feldman, W. Pike, F. Glorieux (Eds.).
124. 3 in basal-lateral membranes of chick intestinal epithelium and relationship to transcaltachia. J Biol Chem 1994, 269:23750-23756.
125. 3. J Cell Biochem 2000, 78:34-46.
126. 3-MARRS)-binding protein in rat IEC-6 cells. Steroids 2005, 70:458-463.
127. Prosser D.E., Guo Y.-D., Geh K.R., et al. Molecular modelling of CYP27A1 and site-directed mutational analyses affecting vitamin D hydroxylation. Biophys J 2006, 90:1-21.
128. Hamamoto H., Kusudo T., Urushino N., et al. Structure-function analysis of vitamin D 24-hydroxylase (CYP24A1) by site-directed mutagenesis: amino acid residues responsible for species-based difference of CYP24A1 between humans and rats. Mol Pharmacol 2006, 70:120-128.
129. 3-26,23-lactone. Proc Natl Acad Sci U S A 2007, 104:12673-12678.
130. Schuster I., Egger H., Nussbaumer P., et al. Inhibitors of vitamin D hydroxylases: structure-activity relationships. J Cell Biochem 2003, 88:372-380.
131. Mellanby E., Cantag M.D. Experimental investigation on rickets. Lancet 1919, 196:407-412.
132. McCollum E.V., Simmonds N., Becker J.E., et al. Studies on experimental rickets. XXI. A demonstration of the existence of a vitamin which promotes calcium deposition. J Biol Chem 1922, 53:293-312.
133. 3. Biochemistry 1968, 7:3317-3322.
134. Fraser D.R., Kodicek E. Unique biosynthesis by kidney of a biologically active vitamin D metabolite. Nature 1970, 228:764-766.
135. Holick M.F., Schnoes H.K., DeLuca H.F., et al. Isolation and identification of 1,25-dihydroxycholecalciferol: a metabolite of vitamin D active in intestine. Biochemistry 1971, 10:2799-2804.
136. 3 made in the kidney. Biochemistry 1972, 11:4251-4255.
137. 3 effective on intestine. J Biol Chem 1973, 248:6691-6696.
138. 3 with intestinal transport activity. Biochemistry 1970, 9:4776-4780.
139. 3 in the rat plasma competitive protein binding radioassay. Biochem Biophys Res Commun 1979, 89:286-293.
140. Park E.A. The therapy of rickets. JAMA 1940, 94:370-379.
141. Baggiolini E.G., Wovkulich P.M., Iacobelli, et al. Preparation of 1α-hydroxylated vitamin D metabolites by total synthesis. Vitamin D: chemical, biochemical and clinical endocrinology of calcium metabolism 1982, 1089-1100. De Gruyter, Berlin. A.W. Norman, K. Schaefer, H. D von (Eds.).
142. 3. Chem Pharm Bull (Tokyo) 1982, 30:4297-4303.
143. 3, a novel vitamin D-related compound with potential therapeutic activity. Tetrahedron Lett 1990, 31:1823-1824.
144. 3 analogues. Chem Pharm Bull (Tokyo) 1986, 34:4410-4413.
145. Calverley M.J. Synthesis of MC-903, a biologically active vitamin D metabolite analog. Tetrahedron 1987, 43:4609-4619.
146. Binderup E., Calverley M.J., Binderup L. Synthesis and biological activity of 1α-hydroxylated vitamin D analogues with poly-unsaturated side chains. Vitamin D: proceedings of the 8th workshop on vitamin D, Paris, France 1991, 192-193. De Gruyter, Berlin. A.W. Norman, R. Bouillon, M. Thomasset (Eds.).
147. Calverley M.J., Binderup E., Binderup L. The 20-epi modification in the vitamin D series: Selective enhancement of " non-classical" receptor-mediated effects. Vitamin D: proceedings of the 8th Workshop on Vitamin D, Paris, France 1991, 163-164. De Gruyter, Berlin. A.W. Norman, R. Bouillon, M. Thomasset (Eds.).
148. Marchiani S., Bonaccorsi L., Ferruzzi P., et al. The vitamin D analogue BXL-628 inhibits growth factor-stimulated proliferation and invasion of DU145 prostate cancer cells. J Cancer Res Clin Oncol 2006, 132:408-416.
149. Morisaki M., Koizumi N., Ikekawa N., et al. Synthesis of active forms of vitamin D. Part IX. Synthesis of 1α,24-dihydroxycholecalciferol. J Chem Soc Perkin 1 1975, 1(1):1421-1424.
150. 3-26,23-lactone depends on the primary structure of the carboxyl-terminal region of the vitamin D receptor. Mol Endocrinol 2005, 19:1147-1157.